Keensight Capital to acquire 3P Biopharmaceuticals from Infraco.

Private equity firm Keensight Capital is set to acquire 3P Biopharmaceuticalss, a leading Contract Development and Manufacturing Organization in Spain, from Infraco. Financial terms were not disclosed. “This is an exciting new chapter for 3P Biopharmaceuticals, we are extremely enthusiastic to work hand in hand with Keensight Capital at such a crucial moment for our industry. With their global footprint and their expertise in the biologics field, I am highly confident that the Keensight team will help us reach significant milestones in the coming years,” Dámaso Molero, 3P Biopharmaceuticals General Manager.